KNSA

+ Watchlist + Portfolio

Kiniksa Pharmaceuticals International, plc

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $80.80
52-Week Range: $32.89 – $82.94
Market Cap: $6.12B
P/E (TTM): 81.74
EPS (TTM): 0.96
Dividend Yield: —

Advanced Metrics

Price/Book: 9.35
PEG Ratio: —
Return on Equity: 14.04%
Return on Assets: 8.05%
Gross Margin: 54.50%
Operating Margin: 11.16%
Profit Margin: 9.59%
Current Ratio: 3.90
Debt/Equity: 0.01
Total Debt: $8.90M
Free Cash Flow: $126.14M
Revenue Growth: 55.40%
Earnings Growth: 30.40%
Enterprise Value: $5.61B

KNSA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$220.18M	$270.26M	$423.24M	$677.56M
Cost of Revenue	$22.89M	$33.41M	$60.91M	$307.22M
Gross Profit	$197.28M	$236.85M	$362.33M	$370.35M
Research & Development	$65.49M	$76.10M	$111.62M	$96.85M
Selling, General & Admin	$97.95M	$129.43M	$168.01M	$196.27M
Operating Expenses	$187.51M	$262.05M	$407.94M	$293.13M
Operating Income	$9.77M	-$25.20M	-$45.62M	$77.22M
EBITDA	$12.18M	-$22.86M	-$43.92M	$78.78M
Pretax Income	$11.03M	-$16.65M	-$36.15M	$88.87M
Income Tax	-$172.34M	-$30.74M	$7.04M	$29.86M
Net Income	$183.36M	$14.08M	-$43.19M	$59.01M
Diluted EPS	2.60	0.20	-0.60	0.75
Diluted Shares	70.42M	71.92M	71.42M	78.98M

KNSA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$122.72M	$107.95M	$183.58M	$165.60M
Receivables	$20.32M	$21.27M	$41.72M	$15.59M
Inventory	$21.60M	$31.12M	$26.36M	$54.90M
Current Assets	$243.06M	$276.30M	$331.80M	$527.18M
Total Assets	$459.67M	$526.32M	$580.55M	$763.63M
Current Liabilities	$47.07M	$63.67M	$100.62M	$139.18M
Total Debt	$5.92M	$12.26M	$9.86M	$9.50M
Total Liabilities	$63.52M	$87.48M	$142.12M	$196.03M
Retained Earnings	-$492.03M	-$477.95M	-$521.14M	-$462.14M
Shareholders' Equity	$396.15M	$438.84M	$438.44M	$567.61M
Working Capital	$195.99M	$212.63M	$231.18M	$387.99M

KNSA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$5.81M	$13.30M	$25.69M	$137.99M
Capital Expenditure	-$105.00K	-$130.00K	-$277.00K	-$1.57M
Free Cash Flow	$5.70M	$13.17M	$25.41M	$136.42M
Depreciation & Amortisation	$2.40M	$2.34M	$1.70M	$1.55M
Stock-Based Compensation	$25.12M	$27.15M	$30.69M	$37.00M
Investing Cash Flow	-$8.08M	-$29.56M	$37.67M	-$188.99M
Financing Cash Flow	$2.52M	$1.50M	$12.27M	$33.02M
Share Repurchases	-$901.00K	-$2.21M	-$4.98M	-$7.73M
Net Change in Cash	$245.00K	-$14.76M	$75.63M	-$17.98M

KNSA Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$156.80M	$180.85M	$202.13M	$214.27M	$243.60M
Cost of Revenue	$71.02M	$83.56M	$90.97M	$96.37M	$111.64M
Gross Profit	$85.78M	$97.29M	$111.15M	$117.89M	$131.96M
Research & Development	$18.75M	$24.17M	$34.61M	$27.48M	$40.90M
Selling, General & Admin	$46.86M	$49.10M	$56.77M	$61.15M	$63.87M
Operating Expenses	$65.62M	$73.27M	$91.38M	$88.63M	$104.77M
Operating Income	$20.16M	$24.02M	$19.77M	$29.27M	$27.19M
EBITDA	$20.52M	$24.41M	$20.23M	$29.73M	$27.67M
Pretax Income	$22.88M	$27.16M	$23.27M	$32.68M	$31.14M
Income Tax	$5.04M	$8.72M	$9.07M	$10.09M	$5.71M
Net Income	$17.83M	$18.43M	$14.20M	$22.59M	$25.43M
Diluted EPS	0.23	0.23	0.17	0.27	0.30
Diluted Shares	77.94M	80.04M	81.57M	82.41M	83.40M

KNSA Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$192.04M	$174.86M	$165.60M	$189.95M	$175.68M
Receivables	$31.91M	$51.74M	$15.59M	$23.22M	$23.49M
Inventory	$48.18M	$41.40M	$54.90M	$73.14M	$70.93M
Current Assets	$420.31M	$475.53M	$527.18M	$594.17M	$668.63M
Total Assets	$661.15M	$712.33M	$763.63M	$825.28M	$896.11M
Current Liabilities	$117.83M	$123.59M	$139.18M	$156.61M	$171.25M
Total Debt	$9.77M	$9.72M	$9.50M	$9.03M	$8.90M
Total Liabilities	$166.14M	$176.95M	$196.03M	$219.59M	$241.96M
Retained Earnings	-$494.77M	-$476.34M	-$462.14M	-$439.55M	-$414.11M
Shareholders' Equity	$495.01M	$535.38M	$567.61M	$605.69M	$654.15M
Working Capital	$302.48M	$351.94M	$387.99M	$437.56M	$497.39M

KNSA Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$28.09M	$33.68M	$53.89M	$50.20M	$47.20M
Capital Expenditure	-$165.00K	-$671.00K	-$633.00K	-$161.00K	-$663.00K
Free Cash Flow	$27.93M	$33.01M	$53.26M	$50.04M	$46.53M
Depreciation & Amortisation	$358.00K	$384.00K	$467.00K	$468.00K	$472.00K
Stock-Based Compensation	$8.88M	$10.14M	$10.23M	$10.06M	$11.64M
Investing Cash Flow	-$3.88M	-$62.76M	-$70.81M	-$31.92M	-$73.58M
Financing Cash Flow	$10.70M	$11.90M	$7.66M	$6.07M	$12.11M
Share Repurchases	-$2.05M	-$4.35M	-$918.00K	-$316.00K	-$5.47M
Net Change in Cash	$34.91M	-$17.18M	-$9.26M	$24.36M	-$14.28M

Market Snapshot

About

Kiniksa Pharmaceuticals International, plc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with inflammatory and autoimmune diseases. The company's pipeline includes multiple programs targeting severe inflammatory conditions with significant unmet medical needs. Kiniksa leverages insights in immunology to develop novel treatments.